Cargando…
A model‐based meta‐analysis of immune‐related adverse events during immune checkpoint inhibitors treatment for NSCLC
Immune checkpoint inhibitors (ICIs) have become a vital part of the therapeutic landscape for non‐small cell lung cancer (NSCLC) in recent years benefiting from their remarkable efficacy. However, ICIs are associated with potentially life‐threatening immune‐related adverse events (irAEs). This study...
Autores principales: | Zhang, Renwei, Kong, Daming, Chen, Rong, Guo, Yuchen, Jian, Weizhe, Han, Mengyi, Zhou, Tianyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381889/ https://www.ncbi.nlm.nih.gov/pubmed/35763678 http://dx.doi.org/10.1002/psp4.12834 |
Ejemplares similares
-
Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019) -
Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023) -
Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023) -
Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023) -
Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)